Guangdong Zhongsheng Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd maintains a strong liquidity position, as evidenced by a current ratio of 4.24, indicating that the company has sufficient current assets to cover its current liabilities multiple times over. However, the company's free cash flow is negative at -92.92 million CNY, which suggests that the company is spending more on capital expenditures than it is generating in operating cash flow. The company's liquidity is assessed as medium, with a key flag indicating that net cash is negative after subtracting total debt. In terms of profitability, the company's return on equity (ROE) is 6.8%, and its return on assets (ROA) is 5.38%. These figures are below the industry median for ROE and ROA, which are typically higher for pharmaceutical companies with strong R&D pipelines and market penetration. The company's gross profit margin is 55.9%, which is in line with the industry average, but its operating margin of 11.8% is slightly below the median for the sector. The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed in the available data. The company operates in a single business segment, which is typical for many pharmaceutical firms in the early stages of international expansion. The lack of geographic diversification may expose the company to regulatory and economic risks specific to the Chinese market. Looking at the company's growth trajectory, the most recent fiscal year saw a revenue of 2.52 billion CNY, which is below the mean analyst estimate of 2.98 billion CNY. The company's earnings per share (EPS) for the last reported period was 0.33 CNY, compared to a mean estimate of 0.47 CNY. This suggests that the company may be underperforming relative to analyst expectations, which could impact investor sentiment and stock valuation. The company's risk profile is characterized by a low dilution risk, as the number of shares outstanding has not changed between basic and diluted shares. However, the company's debt-to-equity ratio of 0.08 indicates a relatively low level of leverage, which is generally favorable for financial stability. The company's capital structure is supported by a total equity of 4.06 billion CNY and total liabilities of 1.07 billion CNY, with long-term debt accounting for 338.33 million CNY. Recent events and disclosures indicate that the company has not issued any new shares or engaged in significant capital raising activities in the recent period. The company's ESG profile is mixed, with a high governance score of 76.79 but a low social pillar score of 13.42 and a high ESG controversies score of 100.00, indicating potential issues in social responsibility and ESG controversies. These factors may influence the company's reputation and access to capital in the future.